V600E is the most commonly encountered BRAF mutation. Braftovi – which Pfizer acquired through its $11.4 billion takeover of Array Biopharma in 2019 – was previously approved in combination ...

There’s been an exciting new development for some patients with metastatic colorectal cancer: a groundbreaking FDA approval has introduced a new treatment option specifically designed for those ...

The focus is on the potential impact of BRAFTOVI for patients with mCRC with a BRAF V600E mutation, reflecting Pfizer's dedication to providing innovative cancer treatments. Based on InvestingPro ...

Personalized Medicine. 2013;10(4):405-412. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict ...

standard of care in untreated BRAF V600E-mutant metastatic colorectal cancer. Results showed patients in the encorafenib/cetuximab plus FOLFOX arm had statistically significant improvement in ...

In combination with trametinib for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. Not for treatment of colorectal cancer ...